NanoSyrinx develops a novel nanosyringe platform to deliver complex biologic payloads selectively. This information is self-described.

NanoSyrinx

NanoSyrinx | 1,743 followers on LinkedIn. NanoSyrinx is developing a novel Biologics drug delivery system for the biopharmaceutical sector. | NanoSyrinx is a cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector.

Jane Dancer

Board Chair, Outrun Therapeutics and Board Member, NanoSyrinx

Anthony G Johnson

Chief Business Officer at NanoSyrinx

James Lapworth

Associate Principal Scientist at Nanosyrinx

Kiran Chintakayala

Kicking off day 3 of #ENASymp24 ! On top of a series of great talks today, we will also be sharing the exciting results from one of our internal projects at poster board #355! If you're sticking around and you're interested in targeted intracellular protein delivery and what we do at NanoSyrinx, come along for a chat with me and Marie McAvoy . EORTC - European Organisation for Research and Treatment of Cancer National Cancer Institute (NCI) American Association for Cancer Research #biotech #drugdelivery #proteindelivery #synbio #intracellulardelivery

Alex Titimeaua

Meet my NanoSyrinx colleagues Alex Titimeaua and Marie McAvoy at #ENASymp24 presenting a poster on payload delivery in Barcelona this week.

Sabine Bowman-Grahl

Hello LinkedIn! Hot on the heels of our recent £10M financing, NanoSyrinx is #hiring . Know anyone who might be interested? For these roles we are looking for experienced scientists with fantastic depth of knowledge who are keen to contribute to an exciting biotech journey! We have 2 live roles currently: 🧬 Preclinical R&D lead for Translational Biology https://lnkd.in/g96FejCJ 🧪 Upstream Bioprocess Lead https://lnkd.in/ggM2ASzH We will have some additional roles coming out in the next few days so please check www.nanosyrinx.com/careers or NanoSyrinx for more details. Any shares/recommendations etc much appreciated. #biotech #syntheticbiology #drugdiscovery #drugdelivery

Joe Healey

Empowering Innovation, Supporting Growth: NanoSyrinx Hits Major Milestone We’re proud to have supported the NanoSyrinx team on their journey. Their recent £10M fundraising round is the latest remarkable step in its outstanding growth. 🔬NanoSyrinx, a synthetic biology company, is developing nanosyringes—a novel platform for targeted intracellular delivery of biologic therapeutics. This technology has the potential to unlock treatments for previously ‘undruggable’ intracellular targets, driving a new wave of medical innovation. Here's how we've supported NanoSyrinx so far : 🚀 Attended our Pre-Accelerator Workshop (2019): Helping to refine their business model and strategy. 💡 Supported in multiple funding rounds (2020-2022): Helping the team to raise the capital needed to scale. 🎟️ Awarded our Golden Ticket in Partnership with AbbVie : One year of free lab space and mentorship. Now, with new funding and the appointment of Dr. Edwin Moses as Chairman, the company continues to push the boundaries of biological therapies. Explore the full story here 👇 https://lnkd.in/eQSuQiNR

Pioneer Group

With the support of Eli Lilly and other investors, NanoSyrinx aims to revolutionize drug delivery using its novel nanosyringe platform. #IntracellularDelivery #DrugDeliveryTech #BiotechFunding #NanoSyrinx #PharmaInnovation #NextGenTherapies

SynBioBeta

Congratulations to NanoSyrinx after completing a £10 million financing round!! #news

Warwick Innovation District

“While huge advances have been made in the field of biologic therapies, the delivery challenge remains a key bottleneck." NanoSyrinx , a synthetic biology company developing nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, has announced that it has closed a 10 million GBP financing round. The company also announced the appointment of Dr. Edwin Moses as Chairman of the Board of Directors. Read more: https://lnkd.in/eQNndesz #MedTech #Funding #NanoSyringes #MedicalDevices

Med-Tech Innovation

📣📣📣HUGE NEWS 📣📣📣 Today we are announcing that NanoSyrinx has completed a £10 million ($13 million) financing round, to accelerate the development of our unique nanosyringe platform for intracellular drug delivery. 🚀 The round was co-led by BGF , Octopus Ventures and M Ventures , with support from new corporate investor, Eli Lilly and Company , and existing investors, IQ Capital and Meltwind Advisory LLP . But there’s more… 😲 We are thrilled to announce that Edwin Moses has joined NanoSyrinx as Chairman, succeeding Stephen Taylor who has led the board since the Company’s inception. As part of the fundraise, we are also delighted to welcome Lucy Edwardes Jones (BGF) to the Board, who will serve alongside existing directors Oliver Sims (Octopus Ventures), Bauke Anninga, PhD (M Ventures), Jane Dancer (Independent) and Anthony G Johnson (Independent). 🗞️ For more details, check out our press release here: https://lnkd.in/eTx89F7C

NanoSyrinx develops a novel 'nanosyringe' platform designed to deliver complex biologic payloads selectively.

news impact assignment basic	general
public peers	general	Nov 5, 2024 12:33 AM	0f6ecc28
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 5, 2024 12:33 AM	93ee18e8
crunchbase trigger	general	Nov 5, 2024 12:33 AM	66450005
crunchbase profile	general
li profile	general	Nov 5, 2024 12:33 AM	129e6076
translate crunchbase fundingrounds	general
peers	general	Nov 5, 2024 12:33 AM	7469a23c
news basic	general	Nov 5, 2024 12:33 AM	791f82d1
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

NANO

COM:NANOSYRINX

NanoSyrinx